Summit Creek Advisors LLC Makes New Investment in BioLife Solutions, Inc. $BLFS

Summit Creek Advisors LLC acquired a new stake in BioLife Solutions, Inc. (NASDAQ:BLFS) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 192,261 shares of the medical equipment provider’s stock, valued at approximately $4,905,000. Summit Creek Advisors LLC owned about 0.40% of BioLife Solutions as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Ameritas Investment Partners Inc. increased its holdings in shares of BioLife Solutions by 12.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock worth $83,000 after acquiring an additional 441 shares during the last quarter. AlphaQuest LLC bought a new position in BioLife Solutions during the second quarter worth $149,000. Strs Ohio acquired a new position in shares of BioLife Solutions in the first quarter valued at $153,000. Tower Research Capital LLC TRC raised its position in shares of BioLife Solutions by 547.9% in the second quarter. Tower Research Capital LLC TRC now owns 7,133 shares of the medical equipment provider’s stock valued at $154,000 after purchasing an additional 6,032 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new position in shares of BioLife Solutions in the second quarter valued at about $205,000. 93.24% of the stock is currently owned by institutional investors.

BioLife Solutions Trading Down 0.4%

NASDAQ BLFS opened at $24.86 on Monday. The company has a market cap of $1.20 billion, a price-to-earnings ratio of -355.09 and a beta of 1.93. The company has a 50 day moving average of $25.41 and a 200-day moving average of $24.88. BioLife Solutions, Inc. has a 1-year low of $19.10 and a 1-year high of $29.62.

Insider Transactions at BioLife Solutions

In related news, CFO Troy Wichterman sold 30,000 shares of the firm’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $25.72, for a total value of $771,600.00. Following the transaction, the chief financial officer owned 152,769 shares in the company, valued at approximately $3,929,218.68. This trade represents a 16.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Greef Roderick De sold 37,795 shares of the firm’s stock in a transaction on Wednesday, October 22nd. The stock was sold at an average price of $27.30, for a total value of $1,031,803.50. Following the completion of the transaction, the chief executive officer owned 489,998 shares in the company, valued at $13,376,945.40. The trade was a 7.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 937,741 shares of company stock worth $26,309,318. Corporate insiders own 2.20% of the company’s stock.

Analysts Set New Price Targets

BLFS has been the topic of a number of research reports. Zacks Research lowered shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 8th. Northland Securities set a $34.00 price objective on BioLife Solutions in a report on Monday, January 5th. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of BioLife Solutions in a research report on Monday, December 29th. Wall Street Zen cut BioLife Solutions from a “buy” rating to a “hold” rating in a report on Sunday, November 30th. Finally, UBS Group restated a “buy” rating on shares of BioLife Solutions in a research note on Monday, December 29th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $32.00.

Key Stories Impacting BioLife Solutions

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: Analyst support that could limit downside — Northland has a $34 target and UBS maintains a buy rating; MarketBeat shows a consensus “Hold” with an average price target near $32, which provides a possible upside reference for investors. MarketBeat BLFS Analyst Coverage
• Neutral Sentiment: Company announced the planned retirement of a key quality & operations executive (effective date/details in the filing). A planned/announced retirement can be orderly but raises succession and continuity questions for manufacturing/quality functions. BioLife announces planned retirement
• Neutral Sentiment: Analysts are issuing Q1 earnings forecasts for BLFS; investors should watch upcoming guidance/quarterly results for confirmation of demand trends in cryopreservation and cell/gene therapy supply chains. Analysts Issue Forecasts for BLFS Q1 Earnings
• Negative Sentiment: Multiple insider sales reported on the same filing period — EVP Aby Mathew sold 405 shares, CMO Todd Berard sold 344 shares, CFO Troy Wichterman sold 990 shares, plus additional smaller officer/insider sales (Sarah Aebersold, Karen Foster). All sales were executed around Jan 6 at ~ $25.59; while sizes are small relative to holdings, clustered executive selling can spook investors. Insider selling report

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.